Patents by Inventor Qiulan DING

Qiulan DING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for preparing and using highly active blood coagulation factor XI mutant and gene therapy/editing vector and recombinant/fusion protein thereof
    Patent number: 11913042
    Abstract: Methods of preparing and using a highly active blood coagulation factor XI mutant and a gene therapy/editing vector thereof and a recombinant/fusion protein thereof. The nucleotide sequence of the mutant is as shown in SEQ ID NOs: 1-6, and the amino acid sequence is as shown in SEQ ID NO: 7.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 27, 2024
    Assignees: RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Xuefeng Wang, Wenman Wu, Qiulan Ding
  • HIGH-ACTIVITY BLOOD COAGULATION FACTOR XI MUTANT ALA570THR
    Publication number: 20230338479
    Abstract: A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 26, 2023
    Applicants: RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Wenman WU, Xuefeng WANG, Qiulan DING
  • METHODS FOR PREPARING AND USING HIGHLY ACTIVE BLOOD COAGULATION FACTOR XI MUTANT AND GENE THERAPY/EDITING VECTOR AND RECOMBINANT/FUSION PROTEIN THEREOF
    Publication number: 20210207115
    Abstract: Methods of preparing and using a highly active blood coagulation factor XI mutant and a gene therapy/editing vector thereof and a recombinant/fusion protein thereof. The nucleotide sequence of the mutant is as shown in SEQ ID NOs: 1-6, and the amino acid sequence is as shown in SEQ ID NO: 7.
    Type: Application
    Filed: August 30, 2018
    Publication date: July 8, 2021
    Applicants: RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Xuefeng WANG, Wenman WU, Qiulan DING